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National Institute of Environmental Health Sciences researchers have invested considerable effort
in exploring the utility of transgenic mice to detect carcinogens and study mechanisms of
carcinogenesis. Work has assessed several mouse models genetically altered to enhance their
expression of chemically induced tumors. Results with the p53def (hemizygous for the tumor-
suppressor gene) and the Tg.AC (carrier of an activated H-ras oncogene) mice have been used as
a basis for a proposed new strategy for identifying chemical carcinogens and assessing risk. The
U.S. National Toxicology Program is conducting a series of studies with these two transgenic
strains to further examine their strengths and weaknesses for identification of documented
rodent and human carcinogens and to explore their ability to provide information concerning the
effective dosimetry for target organ mutation. Environ Health Perspect 106(Suppl 1):81-84
(1998). http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-1/81-84eastin/abstract.html
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History
Federal regulatory agencies such as the
U.S. Environmental Protection Agency
and the U.S. Food and Drug Administra-
tion evaluate all available toxicity data on
specific chemicals or drugs to establish
potential human risk through their use or
exposure to them. For these agencies and
other groups with human health interests,
specific types of data are needed to best
provide an adequate chemical toxicologic
evaluation. Two sources ofthe more criti-
cal data are epidemiologic studies and the
long-term rodent bioassays.
The most relevant data come from
epidemiologic studies because they associ-
ate human health effects with environmen-
tal conditions. When asingle environmental
agent can be shown to be directly related to
a specific health problem in an exposed
population, the risk to humans for that
agent is clear. The fundamental limitation
ofepidemiology is that it is difficult to relate
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a health problem to one environmental
agent because most exposures are to
mixtures of agents and there is an inher-
ently low power to detect an effect. In
addition these studies are retrospective
evaluations ofhazards (1). An additional
complication to the interpretation is that
any study must account for differences in
lifestyles within the exposed population.
In contrast, animal studies allow
single-agent evaluations using appropriate
exposure routes under controlled environ-
mental conditions and these studies may
be prospective. The 2-year bioassay using
both sexes of two rodent species is the
current protocol most commonly used to
produce chemical carcinogenicity data.
This protocol has become fairly standard-
ized (2-5) and data from these studies
generally are required by regulatory agen-
cies to evaluate chemical toxicity from
long-term exposures.
It has been estimated that approximately
70,000 chemicals currently are in use in
commerce (6), most without appropriate
toxicity data. The number of bioassays
completed per year is limited by the
magnitude and length of time it takes to
complete the studies. Thus it would take
decades to provide the data needed to
establish human risk on all chemicals using
the bioassay alone. Yet with this number of
chemicals and the widespread uses ofmany
of them, there is potential for human
exposure and it is important to provide
toxicity data to protect public health.
The U.S. National Toxicology Program
(U.S. NTP) has directly or indirectly pro-
vided a large component ofthe basic scien-
tific data including the 2-year studies that
other federal and state scientific and regula-
tory agencies use to protect human health.
Although still considered the best test
model for obtaining carcinogenicity data,
the 2-year rodent bioassay is limited
because it uses large numbers of animals
and normally takes 5 to 8 years to complete
and evaluate before results are reported,
after which results must be extrapolated
to humans.
One ofthe primary objectives ofthe U.S.
NTP is to develop and validate improved
test methods, including alternative test
systems (7). In addition, the National
Institutes of Health Revitalization Act of
1993 directed the National Institute of
Environmental Health Sciences (NIEHS),
the National Institutes ofHealth's compo-
nent ofthe U.S. NTP, to establish criteria
for the validation and regulatory acceptance
ofalternative testing methods and recom-
mend a process through which scientifically
validated alternative methods can be
accepted for regulatory use (8).
One approach the U.S. NTP is taking
to meet these objectives is evaluation of
alternative models to identify toxic
agents. The overall aim of these evalua-
tions is to develop reliable methods to
test agents for carcinogenicity in a shorter
period of time using fewer animals. The
impetus for the transgenic mouse evalua-
tion came in part from discussions at the
U.S. NTP workshop "Mechanism-Based
Toxicology in Cancer Risk Assessment:
Implications for Research, Regulation,
and Legislation," which was held 11-13
January 1995 in Chapel Hill, NC (9). At
this workshop, Dr. R. Tennant presented
preliminary data from studies under way
in his and other NIEHS laboratories that
suggested Tg.AC and heterozygous
p53def transgenic mice might be good
models to rapidly identify agents with
carcinogenic potential. These studies have
now been published (10,11). Conclusions
from the workshop were that the prelimi-
nary results from transgenic mice were
promising and that further studies includ-
ing validation of the models should
be considered.
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Models
The Tg.AC transgenic line was produced
in FVB/N mice by pronuclear injection of
a v-Ha-rastransgene linked to a fetal 4-glo-
bin promoter and an SV40 polyadenyla-
tion/splice sequence (12). Tg.AC mice
behave like genetically initiated mice,
rapidly developing epidermal papillomas in
response to topical tumor promoter or car-
cinogen treatment. In some experiments
the time to first tumor appearance has been
as short as 3 weeks, but all chemicals tested
that produced papillomas did so in less
than 20 weeks. A dose-response relation-
ship has been observed with promoters and
carcinogens studied to date and in some
studies mice have developed papillomas
too numerous to count. Using the in vitro
Salmonella assay as a measure of muta-
genicity, Tg.AC mice appear to respond to
genotoxic as well as nongenotoxic carcino-
gens. Although the response in treated
mice is dramatic, untreated singly housed
Tg.AC mice do not usually develop any
spontaneous tumors and the histology of
the skin is normal. With respect to mecha-
nisms the v-Ha-ras transgene is not signifi-
cantly expressed in nontumor-bearing
Tg.AC tissues but is overexpressed in the
proliferating component ofbenign and
malignant tumors. Thus, it appears that
expression ofthe transgene drives prolifera-
tion and subsequent tumor development in
carcinogen-treated Tg.AC skin.
The heterozygousp53defmouse line has
one functional wild-typep53allele and one
inactivated nonfunctional allele. The p53
gene is critical to cell cycle control and
DNA repair and one often mutated or lost
in human and rodent tumors (13). Mice
with a single copy of the wild-type p53
allele (p53+1- heterozygous) offer a single
target for mutagens, a condition analogous
to that in humans with some heritable
forms of cancer. The hemizygous state
should increase the probability for either
loss ofp53 tumor-suppressor function or
gain oftransforming activity by requiring
only a single mutation.
Heterozygous p53def mice are viable
and show a low background tumor inci-
dence up to almost 12 months ofage. This
transgenic model is particularly attractive
because in limited studies the same chemi-
cal-specific target organs appear to respond
as in the 2-year bioassay; mice respond
within 6 months and small numbers of
mice can be used to identify the most
serious potential human health risks, i.e.,
chemicals that are mutagenic transspecies
carcinogens (10). These features together
with the observation that thep53 gene has
been shown to be altered in approximately
50% ofhuman cancers, suggests that this
model could be considered as an adjunct
with the short-term assays for mutagenic
chemicals (Salmonella and in vivo rodent
micronucleus assays) as a way ofdetecting
potential human carcinogens.
Studies completed to date suggest that
both the Tg.AC and the p53def transgenic
models are stable within the period oftime
that they were studied (10,11). The pre-
ceding discussion about interpretation of
preliminary NIEHS transgenic mouse
studies is illustrated in Table 1.
Although U.S. NTP researchers are
fully aware ofthe simplistic notion and the
limitations of the distinction typically
drawn between mutagenic and nonmuta-
genic carcinogens, the operational use of
these categories was thought to provide a
convenient framework for testing these
models. The Salmonella parameter was
used as a general index to discriminate
among mutagenic and nonmutagenic
chemicals because extensive studies have
demonstrated that ofall the available geno-
toxicity assays the Salmonella assay segre-
gates most unambiguously with mutagenic
potential. In addition the Salmonella assay
has the highest predictivity for rodent car-
cinogenicity of four in vitro systems com-
monly used to identify chemical mutagenic
potential (14).
Hypotheses
These preliminary transgenic mouse study
results combined with those from the U.S.
NTP 2-year studydata lead to the following
hypotheses.
* Chemicals that are both positive in the
Salmonella in vitro assay and show
cross-species carcinogenic potential in
F344 rats and B6C3F1 mice in 2-year
studies would produce tumors in het-
erozygousp53defand Tg.AC mice.
* Chemicals that were negative in the
Salmonella in vitro assay but showed
cross-species carcinogenic potential
in F344 rats and B6C3F1 mice in 2-
year studies would be negative in the
heterozygous p53def but positive in
Tg.AC mice.
Chemicals that were either positive or
negative in the Salmonella assay and
showed no carcinogenic potential in
F344 rats and B6C3F1 mice in 2-year
studies would be negative in heterozy-
gousp53defandTg.AC mice.
Ifthe pattern oftumor response can be
validated with additional studies, these
two transgenic mice strains may possibly
be used as a screen to identify chemicals
with and without carcinogenic potential.
In addition these studies have the poten-




Based on the transgenic mice study data
(10,11) presented and recommendations
ofparticipants at the "Mechanism-Based
Toxicology in Cancer Risk Assessment:
Implications for Research, Regulation, and
Legislation" workshop (9) and following
the mandate (8) to develop alternative
models, the U.S. NTP decided to test the
hypothesis above by evaluating the het-
erozygous p53def and Tg.AC transgenic
mouse models further to determine their
potential for use in the program.
The purpose ofthe U.S. NTP studies is
not to simply validate the models versus
the rodent 2-year assay but rather to fur-
ther examine their strengths and weak-
nesses for identification of documented
rodent and human carcinogens and to
explore their ability to provide information
concerning the effective dosimetry.
To more fully evaluate the apparent
potential of transgenic mouse models,
studies must be conducted to develop a
database ofresponses of the heterozygous
p53def and Tg.AC strains to the same
chemicals. Only chemicals showing cross-
species carcinogenic potential in 2-year
studies have been tested in the transgenic
mouse lines retrospectively. Chemicals
producing different responses, e.g., those
that cause increased tumor incidences in
a single species or sex or in only a specific
Table 1.Transgenic mice responses based on preliminary results of NIEHS studies (10,11).
NTPstudyresults Predicted transgenic mousetumorresponse
In vitro Salmonellaassay 2-year rodent studies Positive Negative Unknown
Positive Positive p53def, Tg.AC
Negative Positive Tg.AC p53def
Positive Negative p53def,Tg.AC
Negative Negative Tg.AC p53defa
&Chemicals in this categorywere nottested in heterozygous p53def.
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target organ, should also be tested.
Almost all studies in Tg.AC mice have
been topical. To better define this
model, data should be obtained on tumor
responses to chemicals using other routes
of exposure. Fewer chemicals have been
studied with heterozygous p53def; this
database should be expanded. Most
studies in both transgene models have
had limited pathology performed. An
expanded microscopic evaluation of tis-
sues would provide a method of deter-
mining tumorigenic effects similar to that
used in 2-year studies.
Chemical Selection
Chemicals for the initial U.S. NTP
studies were selected to determine if the
models detect human carcinogens, dis-
criminate between carcinogens with dif-
ferent mechanisms of action, or detect
carcinogens administered by more than
one route ofexposure.
When U.S. NTP data were not
available for a particular chemical, the liter-
ature and medical reference books were
used to establish dose levels and target
organs, e.g., for the human carcinogens.
However, where possible, evaluations of
the transgenic mouse model use the U.S.
NTP's historical 2-year rodent carcino-
genicity and Salmonella assay databases as
resources to select chemicals. Candidate
chemicals were placed into one of four
groups based on results ofthe 2-year and
Salmonella studies. Chemicals for consider-
ation were restricted primarily to the more
recent 2-year studies, i.e., those conducted
under the current standardized protocols
and reported after the National Cancer
Institute's Carcinogenesis Bioassay Pro-
gram was transferred to the NIEHS. For
the initial studies only those chemicals with
positive findings in both species and usu-
ally both sexes were categorized as positive
carcinogenicity studies and only those
chemicals with negative results in both
sexes ofboth species were considered nega-
tive carcinogenicity studies. Chemicals
were considered mutagenic ifthere was one
or more positive Salmonella assay response
and nonmutagenic ifthere were only nega-
tive responses. Scientists from both govern-
ment and the private sector were solicited
for comments on the U.S. NTP plan to
evaluate the potential of the transgenic
mouse models and the set of chemicals
selected for these initial studies.
Specific chemicals chosen for the initial
U.S. NTP transgenic mouse studies and
the rationale for their selection are listed in
Table 2 together with the results from
other U.S. NTP studies.
Table 2. Chemicals selected for initial NTPtransgenic mouse studies.
Chemical (proposed mechanism) NTP results Selection rationale (bioassay target organs)
Human carcinogens
Diethylstilbestrol (hormonal) SA- Known to induce cancers in humans and rodents at similar doses. Acts through hormone receptor-mediated process and
2-year + transgenic mice studies will add to our understanding.
Melphalan (genotoxic) SA+ Potent carcinogen thatwill allow the study of a wide dose range and provide information concerning the relative
2-year+ sensitivity ofthe models compared to humans and the bioassay.
Cyclosporin A SA - Mayyield information on the utility ofthese models to identify cancer hazards thatare not readily identified rodent
(immunosuppressive) 2-year - bioassays and arethought to elicit cancerthrough mechanisms otherthan the directalteration of DNA.
Comparison ofeffects of route
ofadministration
N-Methylolacrylamide SA - Negative inp53def; studies in Tg.ACwould add information about proposed response hypothesis.
2-year + In addition, N-methylolacrylamide is well absorbed topically and administration bythis method and an oral
route will provide comparative information on systemic effects. (Target organs: Harderian gland, liver, lung, and ovary;
nervedamage in short-term studies.)
Isomers
2,4-Diaminotoluene SA + To testthe ability ofthetransgenic mouse models to discern differences between closely related chemicals with apparent
2-year+ differences in carcinogenic potential in the rodent bioassay.
Also 2,4-diaminotoluene would provide an additional test on genotoxic chemicals that have caused a less marked tumor
2,6-Diaminotoluene SA+ response than the more potent carcinogens in the 2-year bioassay. (Target organs: 2,4-diaminotoluene, liverand mammary
2-year - gland; 2,6-diaminotoluene, pancreas and liver.)
Model comparison
p-Anisidine SA + To obtain complementary information on a uniform set ofchemicals in thetransgenic models. This agent has been studied
2-year+ inp53def but nottheTg.AC. Itwill also give information on comparative target organ specificity. (Target organ: preputial
gland.)
Noncarcinogens To examine hypothesis that rodentnoncarcinogens will also be negative in thetransgenic species regardless ofmutagenic
activity in Salmonella.
Resorcinol SA - Negative in SAand 2-year butpositive in other genetic toxicity systems. (Target organs: noneobserved.)
2-year -
8-Hydroxyquinoline SA + Positive in SA(mouse lymphoma) butnegative in CHO cells, Drosophila, and 2-year. (Target organs: none.)
2-year -
Rotenone SA - Uniformly negative in SA, CHO cells, and Drosophila. Has apparent anticarcinogenic effects. (Target organs: parathyroid,
2-year - equivocal for2-year; short-term, bone marrow and forestomach.)
Toxic equivalence factors
2,3,7,8-Tetrachlorodibenzo- 2-year + Studies have been done to determine toxic equivalence factors based on relative abilities of dioxinlike chemicals to induce
p-dioxin SA - gene products from activation ofthe Ah receptor.
Demonstration of a response intransgenic(s) would provide a more convenient model to use in further studies ofthe
potency for cancer induction in relation to toxic equivalence factors ofagents in this class. (Target organs: gavage study
thyroid and liver; topical study, integumentary.)
Abbreviations: -, negative; +, positive; CHO, Chinese hamster ovary; SA, in vitro Salmonella assay; 2-year, 2-yearbioassay.
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The U.S. NTP studies described are
currently under way. Preliminary data from
these and additional studies completed by
NIEHS scientists (10,11) are encouraging
and have stimulated the U.S. NTP to plan
future transgenic model studies.
Future Studies
Because these studies require fewer
animals and shorter exposure times, the
use of transgenic models to identify
carcinogens has generated interest among
government and industry scientists. The
U.S. Food and Drug Administration has
decided to accept data from transgenic
models in lieu oftraditional mouse bioas-
say data for new drug registrations. Their
decision is in keeping with the mission
objectives of the International Congress
on Harmonization to examine whether
the need for long-term studies in two
species could be reduced (15). The U.S.
NTP is participating in efforts by the
pharmaceutical industry and other federal
agencies to examine the response of four
transgenic in vivo models systems includ-
ing the Tg.AC and the heterozygous
p53defmice.
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